HC Wainwright assumed coverage on shares of Humanigen (OTCMKTS:HGEN) in a report published on Wednesday, AnalystRatings.net reports. The firm issued a buy rating and a $31.00 price objective on the stock.
Separately, Roth Capital assumed coverage on Humanigen in a research report on Thursday, October 1st. They set a buy rating and a $25.00 price objective for the company.
Shares of Humanigen stock opened at $15.00 on Wednesday. The business has a 50-day moving average price of $10.98 and a 200-day moving average price of $12.97. Humanigen has a twelve month low of $1.50 and a twelve month high of $33.95.
Humanigen (OTCMKTS:HGEN) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter.
In related news, major shareholder Bay Ltd. Nomis sold 300,000 shares of Humanigen stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $5.00, for a total value of $1,500,000.00. Company insiders own 37.50% of the company’s stock.
Humanigen, Inc, a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML).
See Also: Equity Income
Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.